Clinical trials: Immune
Autoimmune Diseases
Exploratory Study on mRNA Therapy Targeting CD19 for the Treatment of Refractory Autoimmune Diseases
Autoimmune diseases, such as immune thrombocytopenia (ITP), immune hemolytic anemia (AIHA), systemic lupus erythematosus (SLE), lupus nephritis (LN), idiopathic inflammatory myopathy (IIM), ulcerative colitis (UC), and systemic…
- Trial name
- NCT07362758
- Testing
- in vivo CAR-T drug based on LNP-mRNA
- Volunteers
- 47 people
- Sponsor
- Xinqiao Hospital of Chongqing
Follicular Lymphoma
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
This single-arm phase II interventional study aims to assess disease response to, and toxicity of, a combination of obinutuzumab and atezolizumab, with or without radiotherapy, in treatment naive Follicular Lymphoma.
- Trial name
- FLUORO (NCT04962126)
- Testing
- Obinutuzumab 25 MG/1 ML Intravenous Solution, Atezolizumab 1200 MG/40mL Intravenous Solution, 4 Gy in 2 fractions
- Where
- 3 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Olivia Newton-John Cancer Research Institute
Rheumatoid Arthritis
Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis
The primary purpose of the protocol is to demonstrate the ability of abatacept plus methotrexate to induce remission in patients with very early rheumatoid arthritis after 12 months of treatment and to maintain remission…
- Trial name
- NCT01142726
- Testing
- Abatacept, Methotrexate
- Where
- 73 sites in United States, Australia and 13 more
- Volunteers
- 511 people
- Sponsor
- Bristol-Myers Squibb
Chronic, Intractable Pain of the Trunk and/or Lower Limbs
Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial
Prospective, multi-center, randomized, single blind study
- Trial name
- DELIVERY (NCT03277378)
- Testing
- lead placement followed by BurstDR stimulation
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 270 people
- Sponsor
- Abbott Medical Devices
HIV Antiretroviral Therapy (ART) Adherence, Alcohol Abuse
Reducing Hazardous Alcohol Use and Optimizing Treatment as Prevention Among Men Living With HIV in Risk Environments
The investigators developed the Kisoboka ("It is possible") Intervention to address limitations of existing evidence-based interventions to optimize treatment as prevention among men living with HIV who drink alcohol at hazardous…
- Conditions
- HIV Antiretroviral Therapy (ART) Adherence, Alcohol Abuse, HIV Infection, Alcohol Use Disorder
- Trial name
- Kisoboka (NCT06771843)
- Testing
- Kisoboka, Behavioral Economics, Motivational Interviewing
- Where
- Uganda
- Volunteers
- 716 people
- Sponsor
- San Diego State University
BCC - Basal Cell Carcinoma, BCC
The Diagnostic Accuracy of Advanced Imaging in Identifying Suspected Skin Cancer (Basal Cell Carcinoma) Around the Eyes
The purpose is to investigate the diagnostic value (sensitivity and specificity) of dermal-Optical Coherence Tomography (D-OCT, VivoSight Dx), in patients with clinically suspected BCC lesions inside the periocular region and…
- Conditions
- BCC - Basal Cell Carcinoma, BCC, Skin Diseases, Eyelid Tumor
- Trial name
- dOCT-pBCC (NCT06279143)
- Where
- Denmark
- Volunteers
- 210 people
- Sponsor
- Vejle Hospital
Ulcerative Colitis
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
Phase 2 induction study with a long-term extension (LTE) period in participants with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT05785715
- Testing
- NX-13 250mg, NX-13 750mg
- Where
- 35 sites in United States, Belgium and 2 more
- Volunteers
- 81 people
- Sponsor
- AbbVie
Primary Immune Deficiency Disorder
Intensive Care Unit and Secondary and Primary Immune Deficiency
Primary immune deficiencies (PID) are characterized by a failure of the immune system that is not explained by any infectious, neoplastic, or iatrogenic cause.
- Trial name
- ICUSPID (NCT02888535)
- Testing
- Internal Medicine consultation
- Where
- France
- Volunteers
- 16 people
- Sponsor
- University Hospital, Caen
Diabetes, Diabetes Mellitus, Type 1
Special Survey for Type 1 or Type 2 Diabetic Patients
This study is conducted in Japan. The aim of this study is to evaluate the incidence of severe hypoglycaemia episodes under normal clinical practice for patients with type 1 or type 2 diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01487408
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 1,463 people
- Sponsor
- Novo Nordisk A/S
Graft vs Host Disease, Bronchiolitis Obliterans
Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans
[Study Objectives] To evaluate the efficacy of azithromycin, N-acetylcystein, and inhaled corticosteroid combination therapy in patients with bronchiolitis obliterans as a complication of allogeneic hematopoietic cell…
- Trial name
- NCT01327625
- Testing
- azithromycin + N-acetylcystein + inhaled corticosteroid
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Asan Medical Center
Multiple Sclerosis
Dry Needling in Multiple Sclerosis
This study is being conducted at the Human Functional Performance Laboratory in the School of Physical Therapy and Rehabilitation Sciences (MDT Building) at the University of South Florida.
- Trial name
- NCT07615725
- Testing
- Dry Needling
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of South Florida
Myasthenia Gravis, Generalized
Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy of CFZ533 as an add-on therapy to standard of care in patients with moderate to severe myasthenia gravis (MG).
- Trial name
- NCT02565576
- Testing
- CFZ533
- Where
- 15 sites in Canada, Denmark and 3 more
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Peanut Allergy
Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children
This is an open-label, follow-up study for subjects who completed the PEPITES study. Subjects will be offered enrollment in this follow-up study to receive Viaskin Peanut 250 μg for 2 additional years if previously on active…
- Trial name
- PEOPLE (NCT03013517)
- Testing
- Viaskin Peanut 250µg
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 300 people
- Sponsor
- DBV Technologies
Asthma
Telephone-Based Program to Promote Inhaled Corticosteroid Adherence Among Individuals With Asthma
Inhaled corticosteroids (ICS) are often prescribed as a treatment for asthma. However, many individuals who take these medications do not adhere to their prescribed treatment regimen.
- Trial name
- NCT00414817
- Testing
- Automated Phone-Based Refill Reminders
- Where
- 2 sites in United States
- Volunteers
- 14,064 people
- Sponsor
- Kaiser Permanente
Influenza A Virus Infection
Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition to standard of care antivirals, in participants hospitalized with severe influenza A infection.
- Trial name
- NCT02572817
- Testing
- High-titer anti-influenza plasma, Low-titer anti-influenza plasma
- Where
- 30 sites in United States
- Volunteers
- 138 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis
Long Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)
Long-term extension of a multi-site, first-in-human study to assess safety and efficacy of an active implantable Vagus Nerve Stimulation (VNS) device in adult patients with active moderate-to-severe rheumatoid arthritis who have…
- Trial name
- NCT04862117
- Testing
- SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- SetPoint Medical Corporation
Atopic Dermatitis
Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)
The purpose of this study was to assess the safety of Dupilumab administered concomitantly with topical corticosteroids (TCS) in patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01639040
- Testing
- Dupilumab, Topical Corticosteroid (TCS)
- Where
- 13 sites in Germany, Hungary and 1 more
- Volunteers
- 31 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
Randomised Placebo Controlled Study of Effects of Therapeutic Hookworm Infection in Asthma
There has been considerable debate over the last 30 years about the interaction between asthma and parasitic infection. It has been suggested that at least part of the reason for the increasing prevalence of asthma in the…
- Trial name
- NCT00469989
- Testing
- Infection with hookworm larvae
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Nottingham
Arthritis, Rheumatoid
The Safety and Effectiveness of Tocilizumab in Rheumatoid Arthritis
The aim of this study is to investigate the safety and effectiveness of tocilizumab (Actemra®) using Chinese Rheumatology Information Platform (CRIP) on Chinese Rheumatology Data Centre (CRDC, http://www.crdc.org.cn/) in Chinese…
- Trial name
- NCT04384068
- Where
- China
- Volunteers
- 2,500 people
- Sponsor
- Peking Union Medical College Hospital
Type I Hypersensitivity
Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen
Tree MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to tree (birch, alder, and hazel) pollen.
- Trial name
- NCT00113750
- Testing
- TreeMATA MPL
- Where
- 10 sites in United States
- Volunteers
- 70 people
- Sponsor
- Allergy Therapeutics